Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures

Rafael E Campo, Jose N. Moreno, German Suarez, Nancimae Miller, Michael A Kolber, Daniel J. Holder, Malathi Shivaprakash, Dana M. DeAngelis, Jennifer L. Wright, William A. Schleif, Emilio A. Emini, Jon H. Condra

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To assess responses to indinavir (IDV)-ritonavir (RTV)-based regimens among HIV-1 infected patients with prior failure of protease inhibitors, and to assess the effects of adherence to therapy and pre-existing genotypic and phenotypic resistance on this response. Methods: Twenty-eight patients initiating salvage regimens with IDV-RTV (800 mg and 200 mg twice daily, respectively) plus one or more reverse transcriptase inhibitor (RTI) were identified retrospectively. Genotypic and phenotypic susceptibilities to multiple antiretroviral agents were determined on viral samples collected at initiation of the salvage regimens, and adherence to therapy was determined through patient self-reporting. Response to therapy (viral RNA ≤ 400 copies/ml) was assessed at the end of and beyond 6 months of follow-up. Results: Based on responses measured in the first 6 months of follow-up, 16 responders and 12 non-responders were identified without differences in baseline demographic factors, laboratory parameters, extent of prior antiretroviral therapy, or characteristics of the RTI components of the new IDV-RTV-based regimens. Adequate adherence was associated with virologic responses (P = 0.005). There were trends for genotypic and phenotypic resistance to be associated with adequate adherence, and, surprisingly, phenotypic resistance to IDV was associated with virologic response rather than with therapeutic failure (P = 0.02). Beyond 6 months of follow-up (mean follow-up 69 weeks), adequate adherence was still associated with virologic response (P = 0.001), but genotypic or phenotypic resistance to IDV were not associated with therapeutic failure. Conclusions: These results suggest that IDV-RTV-based regimens may be able to overcome IDV resistance. This underscores the importance of drug adherence, potency, and exposure in determining virologic responses to antiretroviral therapy.

Original languageEnglish
Pages (from-to)1933-1939
Number of pages7
JournalAIDS
Volume17
Issue number13
DOIs
StatePublished - Sep 5 2003

Fingerprint

Indinavir
Ritonavir
Protease Inhibitors
HIV-1
Reverse Transcriptase Inhibitors
Therapeutics
Anti-Retroviral Agents
Viral RNA
Demography

Keywords

  • Adherence
  • Genotypic resistance
  • Increased drug exposure
  • Indinavir
  • Phenotypic resistance
  • Ritonavir
  • Salvage therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures. / Campo, Rafael E; Moreno, Jose N.; Suarez, German; Miller, Nancimae; Kolber, Michael A; Holder, Daniel J.; Shivaprakash, Malathi; DeAngelis, Dana M.; Wright, Jennifer L.; Schleif, William A.; Emini, Emilio A.; Condra, Jon H.

In: AIDS, Vol. 17, No. 13, 05.09.2003, p. 1933-1939.

Research output: Contribution to journalArticle

Campo, RE, Moreno, JN, Suarez, G, Miller, N, Kolber, MA, Holder, DJ, Shivaprakash, M, DeAngelis, DM, Wright, JL, Schleif, WA, Emini, EA & Condra, JH 2003, 'Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures', AIDS, vol. 17, no. 13, pp. 1933-1939. https://doi.org/10.1097/00002030-200309050-00012
Campo, Rafael E ; Moreno, Jose N. ; Suarez, German ; Miller, Nancimae ; Kolber, Michael A ; Holder, Daniel J. ; Shivaprakash, Malathi ; DeAngelis, Dana M. ; Wright, Jennifer L. ; Schleif, William A. ; Emini, Emilio A. ; Condra, Jon H. / Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures. In: AIDS. 2003 ; Vol. 17, No. 13. pp. 1933-1939.
@article{ab6e58b488704651be1bbd2f40990ee0,
title = "Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures",
abstract = "Objective: To assess responses to indinavir (IDV)-ritonavir (RTV)-based regimens among HIV-1 infected patients with prior failure of protease inhibitors, and to assess the effects of adherence to therapy and pre-existing genotypic and phenotypic resistance on this response. Methods: Twenty-eight patients initiating salvage regimens with IDV-RTV (800 mg and 200 mg twice daily, respectively) plus one or more reverse transcriptase inhibitor (RTI) were identified retrospectively. Genotypic and phenotypic susceptibilities to multiple antiretroviral agents were determined on viral samples collected at initiation of the salvage regimens, and adherence to therapy was determined through patient self-reporting. Response to therapy (viral RNA ≤ 400 copies/ml) was assessed at the end of and beyond 6 months of follow-up. Results: Based on responses measured in the first 6 months of follow-up, 16 responders and 12 non-responders were identified without differences in baseline demographic factors, laboratory parameters, extent of prior antiretroviral therapy, or characteristics of the RTI components of the new IDV-RTV-based regimens. Adequate adherence was associated with virologic responses (P = 0.005). There were trends for genotypic and phenotypic resistance to be associated with adequate adherence, and, surprisingly, phenotypic resistance to IDV was associated with virologic response rather than with therapeutic failure (P = 0.02). Beyond 6 months of follow-up (mean follow-up 69 weeks), adequate adherence was still associated with virologic response (P = 0.001), but genotypic or phenotypic resistance to IDV were not associated with therapeutic failure. Conclusions: These results suggest that IDV-RTV-based regimens may be able to overcome IDV resistance. This underscores the importance of drug adherence, potency, and exposure in determining virologic responses to antiretroviral therapy.",
keywords = "Adherence, Genotypic resistance, Increased drug exposure, Indinavir, Phenotypic resistance, Ritonavir, Salvage therapy",
author = "Campo, {Rafael E} and Moreno, {Jose N.} and German Suarez and Nancimae Miller and Kolber, {Michael A} and Holder, {Daniel J.} and Malathi Shivaprakash and DeAngelis, {Dana M.} and Wright, {Jennifer L.} and Schleif, {William A.} and Emini, {Emilio A.} and Condra, {Jon H.}",
year = "2003",
month = "9",
day = "5",
doi = "10.1097/00002030-200309050-00012",
language = "English",
volume = "17",
pages = "1933--1939",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures

AU - Campo, Rafael E

AU - Moreno, Jose N.

AU - Suarez, German

AU - Miller, Nancimae

AU - Kolber, Michael A

AU - Holder, Daniel J.

AU - Shivaprakash, Malathi

AU - DeAngelis, Dana M.

AU - Wright, Jennifer L.

AU - Schleif, William A.

AU - Emini, Emilio A.

AU - Condra, Jon H.

PY - 2003/9/5

Y1 - 2003/9/5

N2 - Objective: To assess responses to indinavir (IDV)-ritonavir (RTV)-based regimens among HIV-1 infected patients with prior failure of protease inhibitors, and to assess the effects of adherence to therapy and pre-existing genotypic and phenotypic resistance on this response. Methods: Twenty-eight patients initiating salvage regimens with IDV-RTV (800 mg and 200 mg twice daily, respectively) plus one or more reverse transcriptase inhibitor (RTI) were identified retrospectively. Genotypic and phenotypic susceptibilities to multiple antiretroviral agents were determined on viral samples collected at initiation of the salvage regimens, and adherence to therapy was determined through patient self-reporting. Response to therapy (viral RNA ≤ 400 copies/ml) was assessed at the end of and beyond 6 months of follow-up. Results: Based on responses measured in the first 6 months of follow-up, 16 responders and 12 non-responders were identified without differences in baseline demographic factors, laboratory parameters, extent of prior antiretroviral therapy, or characteristics of the RTI components of the new IDV-RTV-based regimens. Adequate adherence was associated with virologic responses (P = 0.005). There were trends for genotypic and phenotypic resistance to be associated with adequate adherence, and, surprisingly, phenotypic resistance to IDV was associated with virologic response rather than with therapeutic failure (P = 0.02). Beyond 6 months of follow-up (mean follow-up 69 weeks), adequate adherence was still associated with virologic response (P = 0.001), but genotypic or phenotypic resistance to IDV were not associated with therapeutic failure. Conclusions: These results suggest that IDV-RTV-based regimens may be able to overcome IDV resistance. This underscores the importance of drug adherence, potency, and exposure in determining virologic responses to antiretroviral therapy.

AB - Objective: To assess responses to indinavir (IDV)-ritonavir (RTV)-based regimens among HIV-1 infected patients with prior failure of protease inhibitors, and to assess the effects of adherence to therapy and pre-existing genotypic and phenotypic resistance on this response. Methods: Twenty-eight patients initiating salvage regimens with IDV-RTV (800 mg and 200 mg twice daily, respectively) plus one or more reverse transcriptase inhibitor (RTI) were identified retrospectively. Genotypic and phenotypic susceptibilities to multiple antiretroviral agents were determined on viral samples collected at initiation of the salvage regimens, and adherence to therapy was determined through patient self-reporting. Response to therapy (viral RNA ≤ 400 copies/ml) was assessed at the end of and beyond 6 months of follow-up. Results: Based on responses measured in the first 6 months of follow-up, 16 responders and 12 non-responders were identified without differences in baseline demographic factors, laboratory parameters, extent of prior antiretroviral therapy, or characteristics of the RTI components of the new IDV-RTV-based regimens. Adequate adherence was associated with virologic responses (P = 0.005). There were trends for genotypic and phenotypic resistance to be associated with adequate adherence, and, surprisingly, phenotypic resistance to IDV was associated with virologic response rather than with therapeutic failure (P = 0.02). Beyond 6 months of follow-up (mean follow-up 69 weeks), adequate adherence was still associated with virologic response (P = 0.001), but genotypic or phenotypic resistance to IDV were not associated with therapeutic failure. Conclusions: These results suggest that IDV-RTV-based regimens may be able to overcome IDV resistance. This underscores the importance of drug adherence, potency, and exposure in determining virologic responses to antiretroviral therapy.

KW - Adherence

KW - Genotypic resistance

KW - Increased drug exposure

KW - Indinavir

KW - Phenotypic resistance

KW - Ritonavir

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=0041327657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041327657&partnerID=8YFLogxK

U2 - 10.1097/00002030-200309050-00012

DO - 10.1097/00002030-200309050-00012

M3 - Article

C2 - 12960826

AN - SCOPUS:0041327657

VL - 17

SP - 1933

EP - 1939

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 13

ER -